3D Medicines (3DMed) has received the CE Mark for its ANDiS real-time polymerase chain reaction (PCR) test for detecting the novel coronavirus, SARS-CoV-2, as well as influenza types A and B.
Respiratory symptoms of SARS-CoV-2 and influenza are similar, and having the capability to screen for both in one test speeds up the diagnostic process, according to the company. All known sequences of SARS-CoV-2 as of February 20 are covered, 3DMed said. The company has also submitted the test to the U.S. Food and Drug Administration for clearance.
